Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Standard care · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Standard care | DRUG | As prescribed |
| beta-lactam | DRUG | 750mg iv q8h |
Inclusion Criteria: * adult patients, \>=18 years of age; * skin or skin structure infection requiring hospitalization; * clinical diagnosis of a skin or skin structure infection caused by bacteria known or suspected to be susceptible to the randomized study treatment; * material from site of infec...
Standard care is a small molecule being studied for the treatment of soft tissue infections. It is currently in Phase 2 clinical development, with one completed trial involving 313 hospitalized patients with skin and skin structure infections. The drug is being developed by Roche Holding AG.
Standard care is being developed by Roche Holding AG, a pharmaceutical company traded under the ticker RHHBY. The drug is in Phase 2 clinical development for soft tissue infections, an infectious disease indication. One clinical trial has been completed to evaluate its use in this setting.
Standard care is in Phase 2 clinical development. It is an investigational small molecule being studied for soft tissue infections. One Phase 2 trial has been completed, and the drug has not yet been approved for any use. It remains under clinical investigation.
Standard care has been studied in one clinical trial, NCT00303589, titled "A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections." This Phase 2 trial was completed and enrolled 313 participants with soft tissue infections across multiple countries, including the United States, Argentina, and Germany.
Standard care is the drug name used in the context of a clinical trial that evaluated a beta-lactam antibiotic. The trial NCT00303589 studied a beta-lactam in hospitalized patients with skin and skin structure infections. Standard care refers to the treatment being investigated in this Phase 2 study.